Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients

Background— Despite a recent American Heart Association (AHA) consensus statement emphasizing the importance of resistant hypertension, the incidence and prognosis of this condition are largely unknown. Methods and Results— This retrospective cohort study in 2 integrated health plans included patients with incident hypertension in whom treatment was begun between 2002 and 2006. Patients were followed up for the development of resistant hypertension based on AHA criteria of uncontrolled blood pressure despite use of ≥3 antihypertensive medications, with data collected on prescription filling information and blood pressure measurement. We determined incident cardiovascular events (death or incident myocardial infarction, heart failure, stroke, or chronic kidney disease) in patients with and without resistant hypertension with adjustment for patient and clinical characteristics. Among 205 750 patients with incident hypertension, 1.9% developed resistant hypertension within a median of 1.5 years from initial treatment (0.7 cases per 100 person-years of follow-up). These patients were more often men, were older, and had higher rates of diabetes mellitus than nonresistant patients. Over 3.8 years of median follow-up, cardiovascular event rates were significantly higher in those with resistant hypertension (unadjusted 18.0% versus 13.5%, P<0.001). After adjustment for patient and clinical characteristics, resistant hypertension was associated with a higher risk of cardiovascular events (hazard ratio, 1.47; 95% confidence interval, 1.33–1.62). Conclusions— Among patients with incident hypertension in whom treatment was begun, 1 in 50 patients developed resistant hypertension. Patients with resistant hypertension had an increased risk of cardiovascular events, which supports the need for greater efforts toward improving hypertension outcomes in this population.

[1]  H. Krum,et al.  Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. , 2012, Circulation.

[2]  Audrey Y. Chu,et al.  Body Mass Index and Risk of Incident Hypertension Over the Life Course: The Johns Hopkins Precursors Study , 2012, Circulation.

[3]  G. Wallukat,et al.  Cytochrome P450 Subfamily 2J Polypeptide 2 Expression and Circulating Epoxyeicosatrienoic Metabolites in Preeclampsia , 2012, Circulation.

[4]  X. Jeunemaître,et al.  Association Between 2 Angiographic Subtypes of Renal Artery Fibromuscular Dysplasia and Clinical Characteristics , 2012, Circulation.

[5]  S. Archer,et al.  GRK2-Mediated Inhibition of Adrenergic and Dopaminergic Signaling in Right Ventricular Hypertrophy: Therapeutic Implications in Pulmonary Hypertension , 2012, Circulation.

[6]  M. Ando,et al.  Percutaneous Transluminal Pulmonary Angioplasty for the Treatment of Chronic Thromboembolic Pulmonary Hypertension , 2012, Circulation. Cardiovascular interventions.

[7]  E. Boerwinkle,et al.  Hypertension Susceptibility Loci and Blood Pressure Response to Antihypertensives: Results From the Pharmacogenomic Evaluation of Antihypertensive Responses Study , 2012, Circulation. Cardiovascular genetics.

[8]  A. Ogawa,et al.  Refined Balloon Pulmonary Angioplasty for Inoperable Patients with Chronic Thromboembolic Pulmonary Hypertension , 2012, Circulation. Cardiovascular interventions.

[9]  F. Blanco,et al.  Oxysterol-Induced Soluble Endoglin Release and Its Involvement in Hypertension , 2012, Circulation.

[10]  Changjin Lee,et al.  Exosomes Mediate the Cytoprotective Action of Mesenchymal Stromal Cells on Hypoxia-Induced Pulmonary Hypertension , 2012, Circulation.

[11]  J. Connell,et al.  Demonstration of Blood Pressure-Independent Noninfarct Myocardial Fibrosis in Primary Aldosteronism: A Cardiac Magnetic Resonance Imaging Study , 2012, Circulation. Cardiovascular imaging.

[12]  J. Afilalo,et al.  A Simple Echocardiographic Prediction Rule for Hemodynamics in Pulmonary Hypertension , 2012, Circulation. Cardiovascular imaging.

[13]  D. Maughan,et al.  Myosin Cross-Bridge Dynamics in Patients With Hypertension and Concentric Left Ventricular Remodeling , 2012, Circulation. Heart failure.

[14]  Vicki L. Burt,et al.  Trends in Antihypertensive Medication Use and Blood Pressure Control Among United States Adults With Hypertension: The National Health and Nutrition Examination Survey, 2001 to 2010 , 2012, Circulation.

[15]  D. Jacobs,et al.  Trends in Blood Pressure and Hypertension Detection, Treatment, and Control 1980 to 2009: The Minnesota Heart Survey , 2012, Circulation.

[16]  Y. Mao,et al.  BMPR2 Mutations Influence Phenotype More Obviously in Male Patients With Pulmonary Arterial Hypertension , 2012, Circulation. Cardiovascular genetics.

[17]  Jeroen J. Bax,et al.  Prognostic Value of Right Ventricular Longitudinal Peak Systolic Strain in Patients With Pulmonary Hypertension , 2012, Circulation. Cardiovascular imaging.

[18]  J. Steiner,et al.  Simultaneous Control of Diabetes Mellitus, Hypertension, and Hyperlipidemia in 2 Health Systems , 2012, Circulation. Cardiovascular quality and outcomes.

[19]  J. McClure,et al.  Activity of the Estrogen-Metabolizing Enzyme Cytochrome P450 1B1 Influences the Development of Pulmonary Arterial Hypertension , 2012, Circulation.

[20]  Des C. Jones,et al.  Impaired Natural Killer Cell Phenotype and Function in Idiopathic and Heritable Pulmonary Arterial Hypertension , 2012, Circulation.

[21]  J. Loscalzo,et al.  Aldosterone Inactivates the Endothelin-B Receptor via a Cysteinyl Thiol Redox Switch to Decrease Pulmonary Endothelial Nitric Oxide Levels and Modulate Pulmonary Arterial Hypertension , 2012, Circulation.

[22]  E. Donal,et al.  Determinants and Prognostic Significance of Exercise Pulmonary Hypertension in Asymptomatic Severe Aortic Stenosis , 2012, Circulation.

[23]  Chun Jimmie Ye,et al.  Integrated Computational and Experimental Analysis of the Neuroendocrine Transcriptome in Genetic Hypertension Identifies Novel Control Points for the Cardiometabolic Syndrome , 2012, Circulation. Cardiovascular genetics.

[24]  A. Capucci,et al.  Relevance of Electrical Remodeling in Human Atrial Fibrillation: Results of the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial Mechanisms of Atrial Fibrillation Study , 2012, Circulation. Arrhythmia and electrophysiology.

[25]  T. Lehtimäki,et al.  The Cardiovascular Risk in Young Finns Study , 2008 .

[26]  W. Elliott,et al.  What is the prevalence of resistant hypertension in the United States? , 2012, Current opinion in cardiology.

[27]  G. Curhan,et al.  Association Between Sodium Intake and Change in Uric Acid, Urine Albumin Excretion, and the Risk of Developing Hypertension , 2012, Circulation.

[28]  T. McKinsey,et al.  Histone Deacetylation Inhibition in Pulmonary Hypertension: Therapeutic Potential of Valproic Acid and Suberoylanilide Hydroxamic Acid , 2012, Circulation.

[29]  A. Ahluwalia,et al.  Dietary Nitrate Ameliorates Pulmonary Hypertension: Cytoprotective Role for Endothelial Nitric Oxide Synthase and Xanthine Oxidoreductase , 2012, Circulation.

[30]  W. Chung,et al.  Whole Exome Sequencing to Identify a Novel Gene (Caveolin-1) Associated With Human Pulmonary Arterial Hypertension , 2012, Circulation. Cardiovascular genetics.

[31]  P. O’Connor,et al.  A Comparison Between Antihypertensive Medication Adherence and Treatment Intensification as Potential Clinical Performance Measures , 2012, Circulation. Cardiovascular quality and outcomes.

[32]  Hilary K. Wall,et al.  National Surveillance Definitions for Hypertension Prevalence and Control Among Adults , 2012, Circulation. Cardiovascular quality and outcomes.

[33]  M. Humbert,et al.  Résultats tardifs de la commissurotomie mitrale percutanée à 20 ans Création et validation d ’ un score de risque prédisant les résultats fonctionnels à long terme à partir d ’ une série de 912 patients , 2012 .

[34]  H. Palevsky,et al.  Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials , 2012, Circulation.

[35]  E. Peterson,et al.  Hypertension Control Among Patients Followed by Cardiologists , 2012, Circulation. Cardiovascular quality and outcomes.

[36]  Ronald E. Jones,et al.  Blood Pressure Control Among US Veterans: A Large Multiyear Analysis of Blood Pressure Data From the Veterans Administration Health Data Repository , 2012, Circulation.

[37]  D. Calhoun,et al.  Resistant hypertension: incidence, prevalence, and prognosis. , 2012, Circulation.

[38]  Albert-László Barabási,et al.  MicroRNA-21 Integrates Pathogenic Signaling to Control Pulmonary Hypertension: Results of a Network Bioinformatics Approach , 2012, Circulation.

[39]  C. Thuillez,et al.  Epoxyeicosatrienoic Acids Contribute With Altered Nitric Oxide and Endothelin-1 Pathways to Conduit Artery Endothelial Dysfunction in Essential Hypertension , 2012, Circulation.

[40]  K. Lim,et al.  Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia , 2012, Circulation.

[41]  M. Leonard,et al.  Gremlin Plays a Key Role in the Pathogenesis of Pulmonary Hypertension , 2012, Circulation.

[42]  R. Burnett,et al.  Air Pollution and Incidence of Hypertension and Diabetes Mellitus in Black Women Living in Los Angeles , 2012, Circulation.

[43]  D. Ypey,et al.  Spontaneous Ventricular Fibrillation in Right Ventricular Failure Secondary to Chronic Pulmonary Hypertension , 2012, Circulation. Arrhythmia and electrophysiology.

[44]  Josef Coresh,et al.  Chronic kidney disease , 2012, The Lancet.

[45]  R. Barst,et al.  A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children With Pulmonary Arterial Hypertension , 2012, Circulation.

[46]  W. Paulus,et al.  Bisoprolol Delays Progression Towards Right Heart Failure in Experimental Pulmonary Hypertension , 2012, Circulation. Heart failure.

[47]  D. Matamis,et al.  Inhaled NO and Sildenafil Combination in Cardiac Surgery Patients With Out-of-Proportion Pulmonary Hypertension: Acute Effects on Postoperative Gas Exchange and Hemodynamics , 2012, Circulation. Heart failure.

[48]  R. Barst,et al.  Survival in Childhood Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management , 2011, Circulation.

[49]  W. Elliott.  Uncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008 , 2012 .

[50]  J. Marrs,et al.  Description of Antihypertensive Use in Patients With Resistant Hypertension Prescribed Four or More Agents , 2011, Hypertension.

[51]  Stephen D. Persell.  Prevalence of Resistant Hypertension in the United States, 2003–2008 , 2011, Hypertension.

[52]  J. Banegas,et al.  Clinical Features of 8295 Patients With Resistant Hypertension Classified on the Basis of Ambulatory Blood Pressure Monitoring , 2011, Hypertension.

[53]  G. Bakris,et al.  Combination Therapy in Hypertension , 2011, Journal of clinical hypertension.

[54]  Heather M. Tavel,et al.  Trends in Time to Confirmation and Recognition of New-Onset Hypertension, 2002-2006 , 2010, Hypertension.

[55]  Heather M. Tavel,et al.  Trends in first-line therapy for hypertension in the Cardiovascular Research Network Hypertension Registry, 2002-2007. , 2010, Archives of internal medicine.

[56]  D. Calhoun,et al.  Characterization and treatment of resistant hypertension , 2009, Current cardiology reports.

[57]  E. Muxfeldt,et al.  Prognostic influence of office and ambulatory blood pressures in resistant hypertension. , 2008, Archives of internal medicine.

[58]  Ong Ht.  Cardiovascular outcomes in the comparative hypertension drug trials: more consensus than controversy. , 2008 .

[59]  D. Goff,et al.  Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. , 2008, Circulation.

[60]  A. Rodgers,et al.  Global burden of blood-pressure-related disease, 2001 , 2008, The Lancet.

[61]  H. Ong.  Cardiovascular outcomes in the comparative hypertension drug trials: more consensus than controversy. , 2008, Singapore medical journal.

[62]  E. Schiffrin,et al.  Chronic Kidney Disease: Effects on the Cardiovascular System , 2007, Circulation.

[63]  J. Steiner,et al.  A Systematic Review of the Literature , 2019, HIV/AIDS and Adolescents.

[64]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[65]  J. Fort.  Chronic renal failure: a cardiovascular risk factor. , 2005, Kidney international. Supplement.

[66]  F. Cuccurullo,et al.  Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. , 2005, American journal of hypertension.

[67]  François Gueyffier,et al.  Systolic and Diastolic Blood Pressure Lowering as Determinants of Cardiovascular Outcome , 2005, Hypertension.

[68]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[69]  Carl J Pepine,et al.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. , 2003, JAMA.

[70]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[71]  Janet S. Dodd,et al.  References , 2003, Dividing Paradise.

[72]  Ihab Hajjar,et al.  Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. , 2003, JAMA.

[73]  J. Staessen,et al.  Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003 , 2003, Journal of hypertension.

[74]  S. Lewington.  Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (vol 360, pg 1903, 2002) , 2003 .

[75]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[76]  B. Davis,et al.  Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). , 2002, Journal of clinical hypertension.

[77]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[78]  Daniel Levy,et al.  Differential Control of Systolic and Diastolic Blood Pressure: Factors Associated With Lack of Blood Pressure Control in the Community , 2000, Hypertension.

[79]  Barry R. Davis,et al.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.

[80]  J. Selby,et al.  Evaluating hypertension control in a managed care setting. , 1999, Archives of internal medicine.

[81]  Wan Ariffin Bin Abdullah.  Singapore Med J , 1993 .

[82]  G. W. Ward.  The National High Blood Pressure Education Program , 1984 .

[83]  S. Shaughnessy,et al.  Do No Harm: Health Systems’ Duty to Promote Clinician Well-Being , 2022, American Journal of Hospital Medicine.